Processa Pharmaceuticals (PCSA) Stock: Phase 2 Breast Cancer Update, 1-for-25 Reverse Split, and What Wall Street Is Watching on Dec. 18, 2025
December 18, 2025 — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is back on traders’ radar after the company reported fresh clinical observations from its Phase 2 breast cancer program and implemented another reverse stock split to consolidate shares. The result: a